U.S. Markets open in 9 hrs 4 mins

Madrigal Pharmaceuticals, Inc. (MDGL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
75.30-8.16 (-9.78%)
At close: 04:00PM EDT
79.01 +3.71 (+4.93%)
After hours: 07:14PM EDT

Madrigal Pharmaceuticals, Inc.

Four Tower Bridge
Suite 200 200 Barr Harbor Drive
West Conshohocken, PA 19428
United States
267 824 2827

Full Time Employees71

Key Executives

NameTitlePayExercisedYear Born
Dr. Paul A. Friedman M.D.Chairman & CEO1.07MN/A1943
Dr. Rebecca A. Taub M.D.Founder, Chief Medical Officer, Pres of R&D and Director830.06kN/A1952
Mr. Brian J. Lynch J.D.Gen. Counsel698.05kN/A1962
Mr. Remy SukhijaChief Commercial Officer714.9kN/A1973
Mr. Alex G. HowarthChief Financial OfficerN/AN/A1969
Dr. Kianoush Motesharei Ph.d.Sr. VP of Bus. & Corp. Devel.N/AN/A1970
Mr. Edward ChiangSr. VP of Clinical & Technical OperationsN/AN/AN/A
Mr. Thomas W. HareSr. VP of Clinical ManagementN/AN/AN/A
Dr. Robert E. Waltermire Ph.D.Chief Pharmaceutical Devel. OfficerN/AN/AN/A
Dr. Stephen Dodge M.B.A., Pharm.D.Sr. VP of Global Medical AffairsN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Corporate Governance

Madrigal Pharmaceuticals, Inc.’s ISS Governance QualityScore as of May 1, 2022 is 7. The pillar scores are Audit: 5; Board: 6; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.